Sodium-glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?

Diabetes Obes Metab. 2022 Oct;24(10):1897-1900. doi: 10.1111/dom.14818. Epub 2022 Aug 5.

Authors

Riccardo Proietti¹, Gregory Y H Lip¹

Affiliation

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.

PMID: 35837983
DOI: 10.1111/dom.14818

No abstract available

Keywords: antidiabetic drug; canagliflozin; cardiovascular disease; clinical trial.

MeSH terms

Atrial Fibrillation* / complications
Atrial Fibrillation* / drug therapy
Canagliflozin
Humans
Hypoglycemic Agents / therapeutic use
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Canagliflozin
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors